Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

The European ALMA Investigators

doi:10.1016/j.leukres.2014.12.013

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

The European ALMA Investigators

Department of Translational Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Hypomethylating agents are able to prolong the overall survival of some patients diagnosed with acute myeloid leukemia. The aim of this study was to evaluate the clinical use of azacitidine as front-line therapy in unfit acute myeloid leukemia (AML) patients and to develop a clinical prediction model to identify which patients may benefit more from the drug. One hundred and ten untreated unfit AML patients received front-line azacitidine therapy in Spain, and response and survival were evaluated in them following European LeukemiaNet (ELN) guidelines. A clinical prediction rule was obtained from this population that was validated and refined in 261 patients treated in France, Austria and Italy. ELN response was achieved in 21.0% of the 371 patients (CI95% 17.0-25.5) and did not depend on bone marrow blast cell percentage. Median overall survival was 9.6 months (CI95% 8.5-10.8) and 40.6% of the patients were alive at 1 year (CI95% 35.5-45.7). European ALMA score (E-ALMA), based on performance status, white blood cell counts at azacitidine onset and cytogenetics, discriminated three risk groups with different survival and response rates. Azacitidine seems a reasonable therapeutic option for most unfit AML patients, i.e. those displaying a favorable or intermediate E-ALMA score.

Original language	English
Pages (from-to)	296-306
Number of pages	11
Journal	Leukemia Research
Volume	39
Issue number	3
DOIs	https://doi.org/10.1016/j.leukres.2014.12.013
Publication status	Published - 1 Mar 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Acute myeloid leukemia
Azacitidine
Elderly
Prediction
Score
Unfit

Access to Document

10.1016/j.leukres.2014.12.013

Cite this

@article{88ddb98e53244d609df6cbb40a010c38,

title = "Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction",

abstract = "Hypomethylating agents are able to prolong the overall survival of some patients diagnosed with acute myeloid leukemia. The aim of this study was to evaluate the clinical use of azacitidine as front-line therapy in unfit acute myeloid leukemia (AML) patients and to develop a clinical prediction model to identify which patients may benefit more from the drug. One hundred and ten untreated unfit AML patients received front-line azacitidine therapy in Spain, and response and survival were evaluated in them following European LeukemiaNet (ELN) guidelines. A clinical prediction rule was obtained from this population that was validated and refined in 261 patients treated in France, Austria and Italy. ELN response was achieved in 21.0\% of the 371 patients (CI95\% 17.0-25.5) and did not depend on bone marrow blast cell percentage. Median overall survival was 9.6 months (CI95\% 8.5-10.8) and 40.6\% of the patients were alive at 1 year (CI95\% 35.5-45.7). European ALMA score (E-ALMA), based on performance status, white blood cell counts at azacitidine onset and cytogenetics, discriminated three risk groups with different survival and response rates. Azacitidine seems a reasonable therapeutic option for most unfit AML patients, i.e. those displaying a favorable or intermediate E-ALMA score.",

keywords = "Acute myeloid leukemia, Azacitidine, Elderly, Prediction, Score, Unfit",

author = "\{The European ALMA Investigators\} and F. Ramos and S. Th{\'e}pot and L. Pleyer and L. Maurillo and R. Itzykson and J. Bargay and R. Stauder and A. Venditti and V. Seegers and V. Mart{\'i}nez-Robles and S. Burgstaller and C. R{\'e}cher and G. Deb{\'e}n and G. Gaidano and C. Gardin and P. Musto and R. Greil and Ferm{\'i}n S{\'a}nchez-Guijo and P. Fenaux and Sylvain Th{\'e}pot and Christian R{\'e}cher and Emmanuel Raffoux and Bruno Quesnel and Jacques Delaunay and Thomas Cluzeau and Koka, \{Anne Marfaing\} and Aspasia Stamatoullas and Chaury, \{Marie Pierre\} and Emmanuel Gyan and St{\'e}phane Cheze and Anne Banos and Pierre Morel and Isabelle Plantier and Taksin, \{Anne Laure\} and Ame Shanti and Laurence Sanhes and \{De Botton\}, Stephane and Marolleau, \{Jean Pierre\} and C{\'e}cile Pautas and Eric Wattel and Francoise Isnard and Agnies Guerci and Norbert Vey and Francois Dreyfus and Norbert Ifrah and Lionel Ades and Violeta Mart{\'i}nez-Robles and Guillermo Deb{\'e}n and Ana Garrido and Javier Casa{\~n}o",

note = "Publisher Copyright: {\textcopyright} 2014 Elsevier Ltd.",

year = "2015",

month = mar,

day = "1",

doi = "10.1016/j.leukres.2014.12.013",

language = "English",

volume = "39",

pages = "296--306",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "3",

}

TY - JOUR

T1 - Azacitidine frontline therapy for unfit acute myeloid leukemia patients

T2 - Clinical use and outcome prediction

AU - The European ALMA Investigators

AU - Ramos, F.

AU - Thépot, S.

AU - Pleyer, L.

AU - Maurillo, L.

AU - Itzykson, R.

AU - Bargay, J.

AU - Stauder, R.

AU - Venditti, A.

AU - Seegers, V.

AU - Martínez-Robles, V.

AU - Burgstaller, S.

AU - Récher, C.

AU - Debén, G.

AU - Gaidano, G.

AU - Gardin, C.

AU - Musto, P.

AU - Greil, R.

AU - Sánchez-Guijo, Fermín

AU - Fenaux, P.

AU - Thépot, Sylvain

AU - Récher, Christian

AU - Raffoux, Emmanuel

AU - Quesnel, Bruno

AU - Delaunay, Jacques

AU - Cluzeau, Thomas

AU - Koka, Anne Marfaing

AU - Stamatoullas, Aspasia

AU - Chaury, Marie Pierre

AU - Gyan, Emmanuel

AU - Cheze, Stéphane

AU - Banos, Anne

AU - Morel, Pierre

AU - Plantier, Isabelle

AU - Taksin, Anne Laure

AU - Shanti, Ame

AU - Sanhes, Laurence

AU - De Botton, Stephane

AU - Marolleau, Jean Pierre

AU - Pautas, Cécile

AU - Wattel, Eric

AU - Isnard, Francoise

AU - Guerci, Agnies

AU - Vey, Norbert

AU - Dreyfus, Francois

AU - Ifrah, Norbert

AU - Ades, Lionel

AU - Martínez-Robles, Violeta

AU - Debén, Guillermo

AU - Garrido, Ana

AU - Casaño, Javier

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Hypomethylating agents are able to prolong the overall survival of some patients diagnosed with acute myeloid leukemia. The aim of this study was to evaluate the clinical use of azacitidine as front-line therapy in unfit acute myeloid leukemia (AML) patients and to develop a clinical prediction model to identify which patients may benefit more from the drug. One hundred and ten untreated unfit AML patients received front-line azacitidine therapy in Spain, and response and survival were evaluated in them following European LeukemiaNet (ELN) guidelines. A clinical prediction rule was obtained from this population that was validated and refined in 261 patients treated in France, Austria and Italy. ELN response was achieved in 21.0% of the 371 patients (CI95% 17.0-25.5) and did not depend on bone marrow blast cell percentage. Median overall survival was 9.6 months (CI95% 8.5-10.8) and 40.6% of the patients were alive at 1 year (CI95% 35.5-45.7). European ALMA score (E-ALMA), based on performance status, white blood cell counts at azacitidine onset and cytogenetics, discriminated three risk groups with different survival and response rates. Azacitidine seems a reasonable therapeutic option for most unfit AML patients, i.e. those displaying a favorable or intermediate E-ALMA score.

AB - Hypomethylating agents are able to prolong the overall survival of some patients diagnosed with acute myeloid leukemia. The aim of this study was to evaluate the clinical use of azacitidine as front-line therapy in unfit acute myeloid leukemia (AML) patients and to develop a clinical prediction model to identify which patients may benefit more from the drug. One hundred and ten untreated unfit AML patients received front-line azacitidine therapy in Spain, and response and survival were evaluated in them following European LeukemiaNet (ELN) guidelines. A clinical prediction rule was obtained from this population that was validated and refined in 261 patients treated in France, Austria and Italy. ELN response was achieved in 21.0% of the 371 patients (CI95% 17.0-25.5) and did not depend on bone marrow blast cell percentage. Median overall survival was 9.6 months (CI95% 8.5-10.8) and 40.6% of the patients were alive at 1 year (CI95% 35.5-45.7). European ALMA score (E-ALMA), based on performance status, white blood cell counts at azacitidine onset and cytogenetics, discriminated three risk groups with different survival and response rates. Azacitidine seems a reasonable therapeutic option for most unfit AML patients, i.e. those displaying a favorable or intermediate E-ALMA score.

KW - Acute myeloid leukemia

KW - Azacitidine

KW - Elderly

KW - Prediction

KW - Score

KW - Unfit

UR - https://www.scopus.com/pages/publications/84924076153

U2 - 10.1016/j.leukres.2014.12.013

DO - 10.1016/j.leukres.2014.12.013

M3 - Article

SN - 0145-2126

VL - 39

SP - 296

EP - 306

JO - Leukemia Research

JF - Leukemia Research

IS - 3

ER -

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this